Cocrystal Pharma, Inc.
COCP Healthcare Biotechnology
In the quarter to June 2026, revenue fell 81.1%, EPS fell 15.0% and free cash flow fell 16.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow COCP
Cocrystal Pharma, Inc. (COCP) EV/Sales
As of 16 October 2026, Cocrystal Pharma, Inc. (COCP) trades at a EV/Sales of 8.9×. Over the past ten years it has ranged from −13.7× (December 2022) to 3,425× (April 2016); the current reading is higher than 47% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 20.9× | 1,517.73% |
| FY2019 | 1.3× | (98.87%) |
| FY2015 | 115× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 9.2× | 78.56% |
| Mar 2026 | 5.2× | (75.29%) |
| Dec 2020 | 20.9× | 83.19% |
| Sep 2020 | 11.4× | (63.69%) |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ATYR aTyr Pharma, Inc. compare | −3.4× |
| NEUP Neuphoria Therapeutics Inc. compare | −0.3× |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| CNTX Context Therapeutics Inc. compare | n/m |
| ANEB Anebulo Pharmaceuticals, Inc. compare | n/m |
| ACGN Aceragen, Inc. compare | 4.1× |
| COCP Cocrystal Pharma, Inc. | 8.9× |
| KYNB Kyntra Bio Inc compare | 16.3× |
| QNTM Quantum Biopharma Ltd. compare | 28.8× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)